- Home
- FMC vs OCS Comparison
FMC vs OCS Comparison
Compare FMC & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMC | OCS |
|---|---|---|
| Founded | 1910 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | 60 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | FMC | OCS |
|---|---|---|
| Price | $11.85 | $11.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | $18.50 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 2.7M | 1.1M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,727,800,000.00 | N/A |
| Revenue This Year | $7.89 | $466.06 |
| Revenue Next Year | $4.54 | $479.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.72 | $10.52 |
| 52 Week High | $44.68 | $34.48 |
Technical Indicators
Market Signals| Indicator | FMC | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 22.63 |
| Support Level | N/A | N/A |
| Resistance Level | $14.31 | $21.82 |
| Average True Range (ATR) | 0.65 | 1.80 |
| MACD | -0.06 | -0.99 |
| Stochastic Oscillator | 36.44 | 3.27 |
Price Performance
Historical ComparisonAbout FMC FMC Corporation
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.